Phreesia (NYSE:PHR) Director Sells $347,206.80 in Stock

Share on StockTwits

Phreesia (NYSE:PHR) Director Michael Weintraub sold 10,680 shares of the business’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $32.51, for a total value of $347,206.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Michael Weintraub also recently made the following trade(s):

  • On Monday, February 10th, Michael Weintraub sold 15,177 shares of Phreesia stock. The stock was sold at an average price of $32.79, for a total value of $497,653.83.

NYSE PHR opened at $32.61 on Friday. Phreesia has a twelve month low of $22.05 and a twelve month high of $34.39. The company has a debt-to-equity ratio of 0.21, a current ratio of 4.01 and a quick ratio of 4.01. The stock has a 50-day simple moving average of $28.93 and a 200 day simple moving average of $27.71.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Tuesday, December 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. The firm had revenue of $32.80 million for the quarter, compared to the consensus estimate of $29.48 million. The business’s revenue for the quarter was up 32.3% compared to the same quarter last year. As a group, analysts predict that Phreesia will post -0.43 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of PHR. TimesSquare Capital Management LLC bought a new position in Phreesia during the third quarter valued at about $29,435,000. FMR LLC increased its stake in Phreesia by 116.2% during the fourth quarter. FMR LLC now owns 2,025,666 shares of the company’s stock valued at $53,964,000 after acquiring an additional 1,088,782 shares during the period. Loomis Sayles & Co. L P bought a new position in Phreesia during the fourth quarter valued at about $16,629,000. Massachusetts Financial Services Co. MA bought a new position in Phreesia during the third quarter valued at about $11,955,000. Finally, Tamarack Advisers LP increased its stake in Phreesia by 230.0% during the fourth quarter. Tamarack Advisers LP now owns 660,000 shares of the company’s stock valued at $17,549,000 after acquiring an additional 460,000 shares during the period. Hedge funds and other institutional investors own 51.49% of the company’s stock.

Several equities analysts recently weighed in on PHR shares. KeyCorp started coverage on Phreesia in a research report on Thursday, January 30th. They set an “overweight” rating and a $36.00 price objective for the company. Zacks Investment Research cut Phreesia from a “buy” rating to a “hold” rating in a research report on Tuesday. Cantor Fitzgerald started coverage on Phreesia in a research report on Wednesday, January 8th. They set an “overweight” rating and a $32.00 price objective for the company. ValuEngine cut Phreesia from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. Finally, Raymond James started coverage on Phreesia in a research report on Thursday, December 19th. They set an “outperform” rating and a $33.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $31.78.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.

Read More: How much money do you need to begin day trading?

Insider Buying and Selling by Quarter for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.